To identify the molecular site of thrombin binding to the platelet membrane, we covalently linked 1251-thrombin to platelets by using the bifunctional chemical cross-linking agents disuccinimidyl suberate and dithiobis(succinimidyl propionate). The proteins cross-linked to 1251-thrombin by this method were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and followed by autoradiography. Two radiolabeled thrombin complexes were identified, a major species of M, -
Introduction
Alpha thrombin is an important and potent activator of platelet function (1) . Although the mechanisms of its action are not completely understood, thrombin appears to bind to specific sites on the platelet surface. Tollefsen et al. (2) defined two classes of binding sites by equilibrium binding studies. One class is characterized by a relatively low surface density (-500 sites/ cell) and by binding at thrombin concentrations corresponding to the threshold at which physiological responses occur (Kd -0.2 nM). The other class is present in greater numbers (-50 ,000 sites/cell) but has a lower affinity for thrombin (Kd 30 nM) and uncertain physiologic significance.
Whether these classes of binding sites represent different membrane structures or negative cooperativity within a single structure has never been clarified, nor have any ofthe membrane structures involved been identified with certainty. Nevertheless, several reports have implicated the membrane glycoprotein lb (GPIb)' as the thrombin receptor. Purified GPIb and its dernvative glycocalicin competitively inhibit thrombin binding to both classes of sites (3, 4) . Yet, Fab fragments of anti-GPIb antisera are reported to have minimal effect on platelet aggregation induced by thrombin (5) . Platelets from patients with BernardSoulier syndrome, which lack GPIb, bind decreased amounts of thrombin (6) . However, these platelets are known to have other membrane abnormalities as well (7) .
We have attempted to identify the platelet receptor for thrombin by chemically cross-linking '251-thrombin to intact platelets with bifunctional cross-linking agents and analyzing the radioactive complexes with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). We have used normal platelets, Bernard-Soulier platelets, and platelets from patients with Glanzmann's thrombasthenia, which lack the membrane glycoprotein Ilb/IlIa (GPIIb/IIIa) complex (8) . In addition, we have studied thrombin binding to normal platelets in the presence of several antibodies specific for certain membrane components and in the presence ofvon Willebrand factor (vWf) and ristocetin. In some instances, the cross-linking studies have been supplemented with binding studies under equilibrium conditions. We have obtained evidence that the platelet has only one binding site for thrombin, and that this is located on GPIb at a point remote from where vWf binds in the presence of ristocetin.
Methods
Human blood was obtained from healthy donors, patients with Glanzmann's thrombasthenia, and patients with the Bernard-Soulier syndrome.
All subjects were informed about the scope of the study. Venipuncture was performed using a 19-gauge needle. Blood was collected into 0.1 volumes of 0.13 M sodium citrate, 10 mM Na2EDTA, in polypropylene tubes. Platelet-rich plasma (PRP) was prepared from normal and throm-basthenic blood by centrifugation at 500 g for 10 min at 240C. Platelets were isolated from this PRP on an arabino-galactan gradient as previously described (9) . Bernard-Soulier PRP was produced by allowing the whole blood to sediment at room temperture for 3 h. Platelets were collected from the Bernard-Soulier PRP by washing away the plasma with salinephosphate-EDTA buffer (0.15 M NaCl, 10 mM sodium phosphate, and 10 mM Na2EDTA, pH 7.4) containing 1% bovine serum albumin (BSA). All platelets were suspended in this buffer, and in some experiments 6 mM N'-ethylmaleimide (NEM) and 1 mM leupeptin were included.
Highly purified alpha thrombin, '-3,000 U/mg, was provided by Dr.
John Fenton, New York State Dept. ofHealth, Albany, NY. The thrombin was iodinated (Na 1251) using agarose-bound lactoperoxidase as previously described (10) . lodination did not alter the fibrinogen clotting activity of the thrombin (1 1). '251-thrombin was treated with diisopropylfluorophosphate (DFP) by the method of Tollefson et al. (2) . Equilibrium binding studies. Isolated platelets were suspended in Tyrode's buffer (0.14 M NaCI, 3 mM KCl, 12 mM NaHCO3, 0.4 mM NaH2PO4, 2 mM CaCI2, and 1 mM MgCI2, pH 7.35) with 5% BSA to give a final concentration of 4.8 X I0/ml normal platelets and 2.4 X 104/ ml Bernard-Soulier platelets. Binding experiments were performed at room temperature by mixing 0.2 ml of the platelet suspensions with 0.2 ml of 251I-thrombin (final concentration, 0.004-8.0 U/ml) in polyethylene tubes. The total radioactivity (cpm) of each sample was measured in an automatic gamma counter (Tracor Analytic, model 1 185). The samples were incubated for 30 min. We (unpublished data) and others (2) have previously shown that binding equilibrium is reached within 10-15 min. After incubation the tubes were centrifuged at 2,000 g for 8 min, and the supernatants aspirated without disturbing the platelet pellets. The radioactivity ofthe tubes was remeasured after aspiration to obtain bound 1251-thrombin. Unbound (supernatant) '251I-thrombin was calculated as total minus bound cpm. Nonspecifically bound thrombin was measured by including hirudin 20 U/ml in the thrombin-platelet mixtures. Radioactivity measurements were converted to units ofthrombin concentration by determining the specific activity of the labeled thrombin (3.3 X 101 cpm/U).
Equilibrium binding of'25I-thrombin in the presence ofvWfand ristocetin or antiglycocalicin antiserum. Platelets (2 X 108/ml) were suspended in saline-phosphate-EDTA buffer containing 1% BSA, 2-100 gg/ml vWf, and ristocetin (0, 1, or 2 mg/ml). 0.2 ml of the platelet suspension was mixed with 0.2 ml of 20 nM 1251-thrombin for 15 min before the cells were isolated by centrifugation. In other experiments, the platelet-thrombin mixtures contained 20% (vol/vol) rabbit antiglycocalicin antiserum obtained from Dr. N. 0. Solum (12) , University of Oslo, Norway, or an equivalent volume ofrabbit preimmune serum with or without hirudin. The concentrations of bound and free thrombin were determined as described above.
Cross-linking protocol. Platelets Solum) were tested. The vWf was purified as previously described (13) . The monoclonal antibody 6D1 is directed against the site on GPIb which vWf binds in the presence of ristocetin (14) . The antibody lOE5 reacts with the GPIIb/IIIa complex where fibrinogen binds (15) .
After incubation, the platelets were rinsed once with saline-phosphate-EDTA and resuspended in the same buffer. The bifunctional cross-linking agents disuccinimidyl suberate (DSS) (16) or dithiobis(succinimidyl propionate) (DSP) ( 17) were freshly prepared. The formation of the radiolabeled cross-linked complexes was followed for 20 s to 60 min by analysis with SDS-PAGE and autoradiography. Although complexes appeared by 40 s and their radioactive intensity stabilized by 80 s, the cross-linking reaction was typically allowed to proceed for 15 min at ice-bath temperature before quenching with 10 or more volumes of ice-cold 10 mM Tris HCI, 1 mM EDTA (pH 7.4 for DSS; pH 8.5 for DSP). This mixture was centrifuged at 2,000 g for 30 min at 250C. The pellet was dissolved in 3.3% SDS with heating at 100I C for 5-10 min. The sample was then centrifuged at 20,000 g for 60 min at 250C. The supernatant was mixed with sample buffer (0.0625 M Tris HCl, 1% SDS, pH 6.8) for electrophoresis.
SDS gel electrophoresis and autoradiography. Samples were heated in sample buffer with or without reducing agent (10 mM dithiothreitol [DTTJ) at 100I C for 5 min before loading onto a 1.5-mm thick slab gel. The Laemmli system of electrophoresis buffers was used (18) . The separating gels were composed of 5% acrylamide, 10% acrylamide, or a composite of 0.5% agarose and 2.25% acrylamide. Stacking gels of 3% acrylamide were used with the 5% gels. After electrophoresis the gels were stained with Coomassie Blue, dried and exposed to X-Omat AR film (Eastman Kodak Co., Rochester, NY) at -70'C. On occasion gels were sliced at 2-mm intervals, and the radioactivity of the individual slices was determined.
Reagents. DSS and DSP were purchased from Pierce Chemical Co. and platelets but no cross-linking agent revealed only an 25I-band that also co-migrated with free thrombin (not shown). These bands seen in the controls corresponded to the most rapidly migrating band ofradioactivity in the cross-linked samples. Furthermore, when the cross-linked samples (formed with the thio-cleavable agent DSP) were treated with a reducing agent (DTT), the two bands of higher Mr disappeared, while the band at M, -38,000 remained. This confirmed that the two bands of higher Mr were in fact due to covalent cross-linking by DSP, and that the band at Mr 38,000 was not a cross-linked species (Fig. 2) .
The same pattern of radioactive bands was present in unreduced samples cross-linked with the noncleavable agent DSS (Fig. 2) . In contrast, under reducing conditions, the middle band with Mr -200,000 migrated slightly further to a position corresponding to Mr -180,000. With 10% SDS-PAGE, only two autoradiographic bands appeared, one at the origin (M, > 180,000) and one at M -38,000, co-migrating with free 1251I thrombin (data not shown).
The intensity of the unreduced middle band on 5% SDS-PAGE was maximal with 0.5 mM and 1 mM DSP (Fig. 1) . At higher concentrations of DSP, less of the cross-linked material could be dissolved in SDS. When 10 mM DSP was used, only 38% of the radiolabeled material remained in the supernatant of samples centrifuged at 20,000 g for 60 min, whereas with 1 mM DSP, 90% ofthe radioactivity remained in the supernatant, and in the absence of DSP 94% remained soluble. Therefore, 1 mM DSP was used in subsequent experiments.
With an initial thrombin concentration of 20 nM and a platelet concentration of 109/ml, -2.5% of the total thrombin in an individual sample became bound to the platelets. With 1 mM DSP, -15% of this platelet-bound "2'I-thrombin migrated with the -200,000-Mr complex, as quantitated by measuring the radioactivity of 2-mm gel slices.
A third band of radioactivity remained at the top of 5% gels (Fig. 1) . In more porous slab gels, however, this band diminished and a faint band appeared with Mr -400,000 (Fig. 3) . On occasion, such slabs were cut into 2-mm slices and the radioactivity ofthe slices quantitated. Regardless of the thrombin concentration used (0.1-20 nM), the ratio of cpm in the -200,000-Mr band to the cpm in the -400,000-Mr band remained 7-10:1. When platelets, unexposed to thrombin, were incubated with DSP and separated by SDS-PAGE, Coomassie Blue staining of the gels revealed a protein pattern similar to that of non-crosslinked platelets, but with a large amount of material remaining at the origin (Fig. 4) .
When hirudin was added to the thrombin-platelet mixtures, subsequent cross-linking with DSP produced no Mr 200,0001251I_ thrombin complex. A faint band was present on 5% SDS-PAGE, corresponding to free thrombin nonspecifically associated with the platelets, and a small amount of radioactivity remained at the top of the gel (Fig. 1, lane H and Fig. 9, lane 3) . Unlabeled thrombin competed with 251I-thrombin for binding to platelets, as shown in Fig. 5 . At a molar ratio of labeled to unlabeled thrombin of 1:1, there was a slight diminution in the appearance of the -200,000-Mr band, and at ratios of 1:100 and 1:500 the radioactive -200,000-Mr band was not seen.
When platelets from a patient with the Bernard-Soulier syndrome (lacking GPIb) were substituted for normal platelets in the cross-linking studies, no radioactive bands appeared at Mr -200,000 or -400,000 in gels of 0.5% agarose and 2.25% acrylamide (Fig. 6 ). To confirm this apparent lack of thrombin binding to the Bernard-Soulier platelets, an equilibrium binding study was performed. A Scatchard plot of the data is shown in Fig. 7 . For comparison, a parallel study with normal platelets is also presented. The only binding demonstrable to the BernardSoulier platelets is represented by a horizontal line (bound/free = 2.3±0.45 ml/10'0 cells, mean±SD), which approximates the asymptote approached by the hyperbolic plot ofthe data for the normal platelets. The intercept of this line also coincides with the constant bound/free ratio observed in the presence ofhirudin (2.6±0.40 ml/10 cells, mean±SD) with free thrombin concentrations of 0.0 1-6 U/ml. By these criteria, the thrombin associated with the Bernard-Soulier platelets represents only nonspecific (unsaturable) binding.
SDS-PAGE ofthe platelets from a patient with Glanzmann's thrombasthenia incubated with thrombin and cross-linking agents is shown in Fig. 8 . Despite the lack of the GPIIb/IIIa complex in these platelets (8) , the radioactive bands derived by thrombin cross-linking were indistinguishable from those seen with normal platelets.
In an attempt to identify the submolecular components of the membrane site(s) involved in thrombin binding, we studied the effect oftwo monoclonal and one polyclonal antibody against platelet glycoproteins. Neither the monoclonal antibody, 6D1, which is directed against the ristocetin-dependent vWf binding site on GPIb, nor the monoclonal antibody, lOE5, which is directed against the fibrinogen binding site on GPIIb/IIIa, altered the appearance of the crosslinked bands appearing on 5% gels. However, the polyclonal antibody against glycocalicin completely inhibited the formation of the '251-thrombin-platelet complexes (Fig. 9) . Preimmune serum had no discernible effect. The inhibition by antiglycocalicin was confirmed by measuring the equilibrium binding of 20 nM thrombin to platelets in the presence of the antibody and in the presence of preimmune serum with and without hirudin. Even though the concentration of antiserum was less in these experiments than in the crosslinking studies (20 vs. 50%, vol/vol), -80% ofthe specific binding at equilibrium was inhibited by the antibody.
Incubating platelets with 1251-thrombin in the presence of vWf and ristocetin appeared to reduce the intensity of the -200,000-Mr band by -20% (Fig. 10 ), whereas vWf alone had no apparent effect. However, equilibrium binding studies with 20 nM thrombin in the presence of ristocetin (1 or 2 mg/ml) and vWf (2-100 ,ug/ml) failed to demonstrate any inhibition (Fig. 11) . Fig. 3 . The arrows indicate radiolabeled species of M, -400,000, -200,000, and -38,000 (dye front). In contrast to normal platelets, the platelets from the Bernard-Soulier patient show only a band that co-migrates with free thrombin. association of thrombin with platelets under equilibrium conditions. As we and others have shown, in the presence of the leech peptide hirudin, the only thrombin binding that occurs is unsaturable, and is equivalent to the nonspecific binding calculated from the limiting value of bound/free on a Scatchard plot ( Fig. 7) (19, 20) . When hirudin was added to '25I-thrombin before mixing with platelets and exposure to a cross-linking agent, the only autoradiographic bands appearing after electrophoretic separation (SDS-PAGE) were very faint, at the top of the gels (to be discussed below) and at Mr -38,000, corresponding to a small amount of free thrombin (Figs. 1 and 9) . Therefore, the '25I bands we observed on SDS-PAGE of samples prepared without hirudin are interpreted to have resulted from the reaction of thrombin with a specific membrane binding site. When normal platelets were cross-linked to 1251-thrombin in the absence of hirudin, a consistent finding was a species with Mr -200,000, compatible in size with a bimolecular complex of one thrombin (Mr -38,000) and one GPIb (Mr -165,000).
In 5% gels, '251I-bands were also detected at the dye front and at the origin (Mr > 350,000). The possibility of complexes of Mr lower than 200,000 was excluded by 10% SDS-PAGE, in which the only bands visualized were at the top of the gel and at Mr -38,000 (uncross-linked thrombin). In gels of0.5% agarose and 2.25% acrylamide, a minor crosslinked species of Mr -400,000 was also evident (Fig. 3) . Although it was not always well separated from the band at Mr -200,000, the absence of any radiolabeled material in the Mr range 200,000-350,000 in 5% gels indicated that the faint band in the more porous system represented a distinct molecular complex rather than a group of complexes of Mr 200,000-400,000. Since there are no recognized membrane proteins sufficiently large to produce a bimolecular unit of this size with thrombin, the Mr -400,000 band must be either (a) a dimer of the -200,000-Mr complex, (b) a heteromultimer of the -200,000-Mr complex and -5 additional 1251-thrombin molecules, or (c) multiple '251-thrombin molecules linked to a membrane protein or group of proteins other than that in the -200,000-Mr band. The latter two possibilities are unlikely both because they would require multiple cross-linking reactions within a single structure and because there is no evidence of the expected family of less cross-linked components of such a conglomerate. Therefore, the most reasonable explanation for the -400,000-Mr complex is that it is a dimer of the -200,000-Mr species. This implies that the thrombin-receptor units in the intact platelet membrane are in close proximity, since the bridging distance of DSP is only 12 A. This possibility has previously been raised by Ganguly and Gould (21) , who suggested that thrombin stimulation may lead to clustering of the thrombin receptors.
In addition to the cross-linked complexes with Mr -200,000 and -400,000, most ofthe polyacrylamide gels retained a variable amount of material at the origin of the lanes, regardless of the porosity of the slab matrix. Although the -400,000-Mr complex would not be expected to enter the 5% gels, the material remaining at the top of these slabs was frequently too concentrated to be explained by this complex alone. Furthermore, small amounts of material remained at the origin ofthe 0.5% agarose, 2.25% acrylamide slabs. Even hirudin, which prevented the formation of cross-linked complexes, did not always eliminate retention of radioactivity at the top of the electrophoretic lanes. Similar observations have been commonly made by others using cross-linking agents (16, 17, 22 Glanzmann's platelets, which lack GPIIb/IIIa, formed crosslinked complexes with 125I-thrombin indistinguishable from those seen with normal platelets (Fig. 8) (Fig. 2) . In the presence of DTT the Mr of the complex, formed with the noncleavable cross-linking agent, decreased by -20,000, consistent with the loss expected by reductive cleavage of the beta (nonglycocalicin) portion of GPIb (Mr 23,000) and the A chain of thrombin (Mr -4,600) (27, 28) . Furthermore, this behavior of the reduced complex implies that the crosslinking is to the B chain of the thrombin molecule.
In an attempt to localize the thrombin binding site even more precisely, the cross-linking studies were performed in the presence of the monoclonal antibody 6D1, which inhibits the ristocetin-dependent binding of vWf to GPIb (14) . This antibody had no apparent effect on formation of the -200,000-Mr complex. Therefore, similar studies were performed to see whether vWf itself would inhibit thrombin binding in the presence of ristocetin. Although the cross-linking studies suggested that the vWf multimers, which are manyfold larger than the 6D1 antibody, might have a moderate inhibitory effect on thrombin binding (-20%), this impression was not confirmed by equilibrium binding methods. Kao et al. (29) found a similar lack of competition ofvWfand thrombin for platelet binding. Therefore, it appears that thrombin binds at a site beyond the realm where steric hindrance from the very large vWf is operative.
In summary, our data are consistent with the conclusion that platelets bind thrombin specifically to a single species of membrane protein, GPIb, despite evidence from equilibrium studies that two functional classes of binding sites exist. Furthermore, this binding occurs between the B chain ofthe thrombin molecule and the glycocalicin portion of GPIb, at a point remote from where vWf binds in the presence of ristocetin.
